New stock news | Bausch Health Hong Kong Stock IPO prospectus invalid

BlissBio Inc. (referred to as Baolisikang) submitted its Hong Kong IPO prospectus on June 29th, which expired after 6 months on December 29th, with Goldman Sachs, Huatai International, and CICC as joint sponsors. The prospectus shows that BlissBio is a clinical-stage biopharmaceutical company dedicated to developing the next generation of antibody-drug conjugates (ADCs) to address important unmet needs in current cancer treatment. The company's core product, BB-1701, is a human epidermal growth factor receptor 2 (HER2)-targeting ado-trastuzumab emtansine (T-DM1) ADC candidate drug, primarily targeting breast cancer (BC), non-small cell lung cancer (NSCLC), and other potential HER2-expressing cancers.